Melanotan I
Men's HealthMen's-health clinics treat Melanotan I as one component in a layered hormonal optimisation framework. The non-cyclic α-MSH analogue with selective MC1R activity — FDA-approved as an implant for erythropoietic protoporphyria. The relevant questions for male users are: does it interact with the HPG axis, is it compatible with current TRT or HCG protocols, and what are its effects on prostate, hematocrit, and cardiovascular indices over a ~2-30 days (implant); ~30 min SubQ-pharmacokinetics Melanotan I cycle? The sections below address each.
Key Takeaways
Male-physiology lens: Melanotan I is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations. Mechanism: Selective melanocortin-1 receptor (MC1R) agonist. Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel. Male dose: 0.5-1 mg 1x daily during loading; less frequent maintenance via subq/implant (approved formulation); cycle 8-12 weeks. Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.
Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. For men, the downstream consequences of this mechanism are evaluated against four operational domains: HPG-axis interaction, recovery and body composition, sexual function and prostate, and integration with concurrent TRT or HCG protocols. Melanotan I's relationship to each is examined below.
Interaction with the HPG axis
Melanotan I's relationship to the male HPG axis is one of the central practical questions. Direct receptor-level engagement of the HPG axis is not the principal mechanism, but downstream effects on testosterone, LH/FSH, and prolactin can still occur and warrant baseline and follow-up labs in male users. The practical takeaway is that any male user beginning a course of Melanotan I should have a baseline hormone panel and a follow-up at 6–8 weeks to detect drift.
Male body composition and performance response
Male users typically respond to Melanotan I on the recovery, lean-mass, or visceral-fat dimension depending on the compound's primary pharmacology. Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. For men whose body composition goals are driven by training, the dose-timing relative to workouts and sleep is often the critical lever rather than the absolute dose itself.
Sexual function and prostate considerations
Where Melanotan I alters circulating LH, testosterone, or local androgen signalling, prostate considerations become relevant for men over 40. Baseline PSA, periodic re-check, and avoidance of stacking that compounds androgenic load are all reasonable precautions. For molecules whose effects are predominantly outside the HPG axis, the prostate consideration is largely background.
Testosterone Optimisation in men responds to Melanotan I with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
Where male users target trt compatibility, Melanotan I is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.
For body composition (male) in male users, Melanotan I is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
Sperm Quality in men responds to Melanotan I with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 0.5-1 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.5-1 mg | 4–6 weeks initial cycle |
| Men's Health focus | SubQ | 0.5-1 mg | 1x daily during loading; less frequent maintenance |
| Maintenance phase | SubQ | 1.5-1 mg | Ongoing with periodic pauses |
Dose timing for Melanotan I is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Melanotan I stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.
- Melanotan I + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Melanotan I's mechanism in male physiology protocols.
- Melanotan I + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with Melanotan I's mechanism in male physiology protocols.
- Melanotan I + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with Melanotan I's mechanism in male physiology protocols.
- Melanotan I + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Melanotan I's mechanism in male physiology protocols.
Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history.
Lens-specific safety considerations for male physiology use of Melanotan I: Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history. Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Melanotan I | α-MSH analogue (long-acting) | ~2-30 days (implant); ~30 min SubQ | Men's Health |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| Gonadorelin (GnRH) | Hypothalamic decapeptide | ~2-4 min | The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
Is Melanotan I compatible with TRT?
How does Melanotan I affect the HPG axis?
Can I use Melanotan I during a cut?
Will Melanotan I affect fertility or sperm quality?
How does Melanotan I compare to Kisspeptin and Gonadorelin (GnRH)?
How should Melanotan I be stored and reconstituted?
Start a Melanotan I Protocol
Alukard provides physician-supervised men's health protocols with GMP-certified Melanotan I and GMP-certified compounds with comprehensive hormone panels.
Get ProtocolQuick Facts
- Molecular weight
- 1646 Da
- Sequence length
- 13 aa
- Half-life
- ~2-30 days (implant); ~30 min SubQ
- WADA
- Not on prohibited list
- FDA
- Approved (Scenesse implant for EPP)
- Research
- Phase III in EPP; off-label tanning use
All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan I unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Male Physiology Protocol for Melanotan I
Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.
HIPAA Compliant · GMP Certified · Physician Supervised